Paradoxical High-Density Lipoprotein Reduction Induced by Fenofibrate and Ciprofibrate

High-density lipoprotein and cardiovascular risk reduction: promises and realities.

In a recent article in the Revista Española de Cardiologı́a, Cordero et al. reported a study of the concentrations of high-density lipoprotein cholesterol (HDL-C) in 959 unselected consecutive patients who were admitted for chest pain. The authors found that low levels of HDL-C (<40 mg/dL) were independently associated with diagnosis of acute coronary syndrome (ACS), that is, the lower the level...

Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.

This study examines the kinetic basis for the increment in plasma low density lipoprotein (LDL) levels that accompanies the fenofibrate treatment of severely hypertriglyceridemic (HTG) patients. Seven HTG men with a mean plasma triglyceride level of 1470 mg/dl were treated for 6 weeks. During treatment, their plasma triglyceride level fell by 77% and their cholesterol level by 41%. The fall in ...

High density Lipoprotein; What to Measure: Quality or Quantity?

High -density lipoprotein cholesterol as a predictor for diabetes mellitus

Background: Diabetes is a prevalent chronic disease around the world. To evaluate risk of diabetes comprehensively, we developed a score model for the risk prediction with HDL-C as a protective factor. Methods: We extracted physical examination data of 2728 individuals. The data contain 18 demographic and clinical variables. To identify the statistical significant feature variables, the backwa...

Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.

PURPOSE OF REVIEW Despite optimally reducing low-density lipoprotein cholesterol (LDL-C) levels to recommended targets using intensive statin therapy, the risk of cardiovascular disease (CVD) remains significant. Low levels of high-density lipoprotein cholesterol (HDL-C; <1.03 mmol/l or <40 mg/dl) are an independent risk factor for CVD, and raising levels of HDL-C is a major treatment strategy ...